The anti-inflammatory drug sulfasalazine is an established and effective treatment for inflammatory bowel disease and various forms of arthritis. The successful use of sulfasalazine (2mg/d) in 8 of 11 patients with LE has been reported (Delaporte et al. 1997). Drug metabolism could be one possible explanation for this discrepancy, since responders belonged to the group of rapid acetylators and nonresponders were slow acetylators. Moreover, no serious toxicity was noted in this small open-label clinical trial. In contrast, another study reported drug eruptions in five of six patients being treated with sulfasalazine, and in only two patients was a beneficial effect observed (Lagrange et al. 1998).
Was this article helpful?